Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome

Cancer Immunology, Immunotherapy

Volumn 63, Issue 12, 2014, Pages 1329-1340

  Foureau, David M ^a   Amin, Asim ^a   White, Richard L ^a   Anderson, William ^a   Jones, Chase P ^a   Sarantou, Terry ^a   McKillop, Iain H ^a   Salo, Jonathan C ^a  

^a LEVINE CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Immune monitoring; Interleukin 2; Melanoma; Renal cell carcinoma

Indexed keywords

ALPHA2 INTERFERON; CD103 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR4; DENDRITIC CELL VACCINE; EVEROLIMUS; INTERLEUKIN 2; IPILIMUMAB; LACTATE DEHYDROGENASE; PAZOPANIB; PEGINTERFERON ALPHA2B; SORAFENIB; SUNITINIB; TICILIMUMAB; TRANSCRIPTION FACTOR FOXP3; VEMURAFENIB;

ADULT; ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CELLULAR DISTRIBUTION; CIRCULATING TUMOR CELL; DRUG MEGADOSE; DRUG WITHDRAWAL; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HOSPITAL DISCHARGE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; KIDNEY METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REGULATORY T LYMPHOCYTE; RETREATMENT; SEX DIFFERENCE; SYSTEMIC THERAPY; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; CARCINOMA, RENAL CELL; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MELANOMA; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

CARCINOMA, RENAL CELL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84916244199     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1605-0     Document Type: Article

References (23)

1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105–2116
2. Riker AI, Radfar S, Liu S, Wang Y, Khong HT (2007) Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther 7(3):345–358. doi:10.1517/14712598.7.3.345
3. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316(15):889–897. doi:10.1056/NEJM198704093161501
4. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI (2010) Treatment of metastatic renal cell carcinoma. Nat Rev Urol 7(6):327–338. doi:10.1038/nrurol.2010.57
5. Ma A, Koka R, Burkett P (2006) Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 24:657–679. doi:10.1146/annurev.immunol.24.021605.090727
6. Boyman O, Sprent J (2012) The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 12(3):180–190. doi:10.1038/nri3156
7. Foureau DM, McKillop IH, Jones CP, Amin A, White RL, Salo JC (2011) Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model. Cancer Immunol Immunother 60(9):1347–1356. doi:10.1007/s00262-011-1035-1
8. Garibal J, Laforge M, Silvestre R, Mouhamad S, Campillo-Gimenez L, Levy Y, Estaquier J (2012) IL-2 immunotherapy in chronically SIV-infected Rhesus macaques. Virol J 9:220. doi:10.1186/1743-422X-9-220
9. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR et al (1993) Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11(10):1969–1977
10. Curran SD, Muellner AU, Schwartz LH (2006) Imaging response assessment in oncology. Cancer Imaging 6:S126–S130. doi:10.1102/1470-7330.2006.9039
11. Kirkwood JM, Tarhini AA (2009) Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol 27(16):2583–2585. doi:10.1200/JCO.2008.21.1540
12. McDermott DF, Regan MM, Atkins MB (2006) Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials. Clin Genitourin Cancer 5(2):114–119. doi:10.3816/CGC.2006.n.027
13. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K (2007) Single-agent interleukin-2 in the treatment of metastatic melanoma. Curr Oncol 14(1):21–26
14. White RL Jr, Amin A (2011) Cancer immunotherapy. Surg Oncol Clin N Am 20(3):531–554, ix. doi:10.1016/j.soc.2011.01.010
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216
16. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM (2009) “MIATA”-minimal information about T cell assays. Immunity 31(4):527–528. doi:10.1016/j.immuni.2009.09.007
17. Kmieciak M, Gowda M, Graham L, Godder K, Bear HD, Marincola FM, Manjili MH (2009) Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J Transl Med 7:89. doi:10.1186/1479-5876-7-89
18. Khattak M, Fisher R, Turajlic S, Larkin J (2013) Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol 5(2):105–118. doi:10.1177/1758834012466280
19. Friedlander P, Hodi FS (2010) Advances in targeted therapy for melanoma. Clin Adv Hematol Oncol 8(9):619–627
20. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B (2012) Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104(2):93–113. doi:10.1093/jnci/djr511
21. Cunningham-Rundles C, Bodian C, Ochs HD, Martin S, Reiter-Wong M, Zhuo Z (2001) Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency. Clin Immunol 100(2):181–190. doi:10.1006/clim.2001.5052
22. Smith-Garvin JE, Koretzky GA, Jordan MS (2009) T cell activation. Annu Rev Immunol 27:591–619. doi:10.1146/annurev.immunol.021908.132706
23. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY (2005) A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6(11):1142–1151. doi:10.1038/ni1263